Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health Economics Review
Published in: Health Economics Review 1/2013

Open Access 01-12-2013 | Research

The high cost of celiac disease in an Israeli Health Maintenance Organization

Authors: Anthony D Heymann, Moshe Leshno, Ronit Endevelt, Raanan Shamir

Published in: Health Economics Review | Issue 1/2013

Login to get access

Abstract

Background

The aim of this study was to identify costs in patients diagnosed with Celiac disease.

Methods

This retrospective case control study covered the period 2003–2006 and was conducted in a large Israeli Health Maintenance Organization insuring over two million members. Our cohort comprised 1,754 patients with Celiac disease with a control group of 15,040. Costs were aggregated according to main cost-branches and computed individually for each member. A linear step wise regression was performed with costs being the dependent variable and the independent variables; age, gender and the presence of celiac disease. Costs were compared with patients suffering from other chronic diseases.

Results

The total costs of the patients with celiac disease were significantly higher than that of the control group for hospital admission, medications, laboratory and imaging. Hospital admission rate was 7.98% as opposed to 7.1% for the control group (p = 0.06). When compared with other chronic illnesses, the costs of patients with celiac disease were similar to those of patients with diabetes and hypertension.

Conclusions

Patients with Celiac disease utilize medical services more than the general population. This research suggests that the use of medical resources by patients with Celiac disease may be higher than previously thought.
Appendix
Available only for authorised users
Literature
1.
Green PH, Cellier C: Celiac disease. N Engl J Med 2007, 357: 1731–1743. 10.1056/NEJMra071600CrossRef
2.
Bingley PJ, Williams AJ, Norcross AJ, Unsworth DJ, Lock RJ, Ness AR, Avon Longitudinal Study of Parents and Children Study Team, et al.: Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ 2004,328(7435):322–323. 10.1136/bmj.328.7435.322PubMedCentralCrossRef
3.
Coeliac Disease:: Recognition and Assessment of Coeliac Disease [Internet]. Editors Centre for Clinical Practice at NICE (UK). Source London: National Institute for Health and Clinical Excellence (UK); 2009 May. National Institute for Health and Clinical Excellence: Guidance.
4.
Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al.: The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010, 42: 587–595. 10.3109/07853890.2010.505931CrossRef
5.
Delcò F, El-Serag HB, Sonnenberg A: Celiac sprue among US military veterans: associated disorders and clinical manifestations. Dig Dis Sci 1999,44(5):966–972. 10.1023/A:1026660614372CrossRef
6.
Shamir R, Lerner A, Shinar E, Lahat N, Sobel E, Bar-Or R, et al.: The use of a Single Serological Marker Underestimates the Prevalence of Celiac disease in Israel: a Prevalence Study of Blood Donors. Am J Gastroenterol 2002, 97: 2589–2594. 10.1111/j.1572-0241.2002.06028.xCrossRef
7.
Godfrey JD, Brantner TL, Brinjikji W, Christensen KN, Brogan DL, Van Dyke CT, et al.: Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010,139(3):763–769. 10.1053/j.gastro.2010.05.041PubMedCentralCrossRef
8.
Cosnes J, Cellier C, Viola S, et al.: Increased autoimmune diseases when not on a gluten free diet. Clin Gastroenterol Hepatol 2008,6(7):753–758. 10.1016/j.cgh.2007.12.022CrossRef
9.
Hershcovici T, Leshno M, Goldin E, Shamir R, Israeli E: Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. Aliment Pharmacol Ther 2010,31(8):901–910.
10.
Green PHR, Stavropoulos SN, Panagi SG, Goldstein SL, McMahon DJ, Absan H, et al.: Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001,96(1):126–131. 10.1111/j.1572-0241.2001.03462.xCrossRef
11.
Mearin ML, Ivarsson A, Dickey W: Coeliac disease: is it time for mass screening? Best Pract Res Clin Gastroenterol 2005,19(3):441–452. 10.1016/j.bpg.2005.02.004CrossRef
12.
Byass P, Kahn K, Ivarsson A: The global burden of childhood coeliac disease: a neglected component of diarrhoeal mortality? PLoS One 2011,6(7):e22774. 10.1371/journal.pone.0022774PubMedCentralCrossRef
13.
Greco L, Timpone L, Abkari A, Abu-Zekry M, Attard T, Bouguerrà F, et al.: Burden of celiac disease in the Mediterranean area. World J Gastroenterol 2011,17(45):4971–4978. 10.3748/wjg.v17.i45.4971PubMedCentralCrossRef
14.
Catassi C, Anderson RP, Hill ID, Koletzko S, Lionetti E, Mouane N, et al.: World perspective on celiac disease. J Pediatr Gastroenterol Nutr 2012,55(5):494–499. 10.1097/MPG.0b013e318272adf4CrossRef
15.
Violato M, Gray A, Papanicolas I, Ouellet M: Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis. PLoS One 2012,7(7):e41308. 10.1371/journal.pone.0041308PubMedCentralCrossRef
16.
Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, Chinburapa V: Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med 2008,40(3–4):218–228.
17.
Long KH, Rubio-Tapia A, Wagie AE, et al.: The economics of coeliac disease: a population-based study. Aliment Pharmacol Ther 2010,32(2):261–269. 10.1111/j.1365-2036.2010.04327.xPubMedCentralCrossRef
18.
Aggarwal S, Lebwohl B, Green P: Screening for celiac disease in average-risk and high-risk populations. Therap Adv Gastroenterol 2012,5(1):37–47. 10.1177/1756283X11417038PubMedCentralCrossRef
19.
Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, Erdtmann F, et al.: Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009,137(1):88–93. 10.1053/j.gastro.2009.03.059PubMedCentralCrossRef
20.
Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, Coeliac EU Cluster, Project Epidemiology, et al.: The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010,42(8):587–595. 10.3109/07853890.2010.505931CrossRef
21.
Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995,57(1):289–300.
22.
Shalev V, Chodick G, Bialik M, Green MS, Heymann AD: In a population-based cohort of diabetes patients, men and women had similar risks for all-cause mortality. J Clin Epidemiol 2007,60(1):86–93. 10.1016/j.jclinepi.2006.04.010CrossRef
Metadata
Title
The high cost of celiac disease in an Israeli Health Maintenance Organization
Authors
Anthony D Heymann
Moshe Leshno
Ronit Endevelt
Raanan Shamir
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2013
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/2191-1991-3-23

Other articles of this Issue 1/2013

Health Economics Review 1/2013 Go to the issue

Research

Impact of educational intervention on willingness-to-pay for health insurance: A study of informal sector workers in urban Bangladesh

Research

National health insurance, social influence and antenatal care use in Ghana

Research

Short term cost effectiveness of a regional myocardial infarction network

Research

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Research

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?

Research

Simulation model for cost estimation of integrated care concepts of heart failure patients